Senomorphic Drug Discovery Services

Senescent cells are a hallmark of aging and have been implicated in numerous age-related diseases. Senescence-associated secretory phenotype (SASP) factors secreted by senescent cells can induce inflammation and fibrosis, altering the behavior of neighboring cells. Unlike senolytics (SASP inhibitors), which aim to eliminate senescent cells, senomorphics seek to alter the phenotype of these cells to reduce their detrimental effects on tissue health.

Fig. 1 General hallmarks of cellular senescence and action mechanisms of senolytic versus senomorphic compounds. (Zhang L, et al., 2023)

At CD BioSciences, we offer a comprehensive suite of senomorphic drug discovery services to help clients facilitate the identification and development of novel senotherapeutics. We customize drug discovery solutions based on specific client needs, ensuring that each project meets its unique objectives.

Overview of Our Senomorphic Drug Discovery Services

At CD BioSciences, we employ a systematic and multi-faceted approach to senomorphic drug discovery, ensuring that our clients receive comprehensive support throughout the entire process.

• Target identification and validation. We use advanced bioinformatics tools to analyze genomic and proteomic datasets to identify potential senescence-associated and inflammation-associated pathways. We also assist in discovering SASP factors and other biomarkers that can be used to measure senescence and the effectiveness of senomorphics.
• Drug screening. CD BioSciences offers access to extensive libraries for high-throughput screening. We also help clients develop and optimize assays tailored to assess potential senomorphics' impacts on senescence-related pathways, ensuring high sensitivity and specificity.
• Analysis of the effects of senomorphics on senescent phenotypes. We provide detailed analysis services to elucidate how senomorphic drugs affect senescent cells, including signaling pathways and gene expression changes. Focusing on the biological effects of senomorphics on senescent cells, we assess parameters such as cell viability, senescence-associated β-galactosidase activity, and secretory phenotype changes. Utilizing genetically modified mouse models, we help clients evaluate the therapeutic efficacy of candidate drugs in vivo, assessing their effects on aging-related phenotypes.

What Targets Do We Focus On in Senomorphic Drug Discovery?

In senomorphic drug discovery services, CD BioSciences focuses on key signaling pathways and molecular targets that are known to play critical roles in regulating cellular senescence and the secretion of the SASP. We help clients develop senomorphics, such as the p38 mitogen-activated protein kinase (p38 MAPK) inhibitors, mammalian target of rapamycin (mTOR) inhibitors, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) inhibitors, Janus kinase (JAK) 1/2 inhibitors, AMP-activated protein kinase (AMPK) activators, etc.

CD BioSciences offers a range of services that facilitate the discovery and development of senomorphic drugs, which have applications across various aging-related diseases, such as cancer, cardiovascular diseases, and neurodegenerative disorders. Our approach minimizes disruption to normal cellular functions, thereby reducing the likelihood of adverse side effects. If you are interested in our services, please feel free to contact us or make an online inquiry.

Reference

1. Zhang L, et al. Targeting cellular senescence with senotherapeutics: senolytics and senomorphics. FEBS J, 2023, 290 (5): 1362-1383.